Data-Driven Prediction of the Formation of Co-Amorphous Systems

Co-amorphous systems (COAMS) have raised increasing interest in the pharmaceutical industry, since they combine the increased solubility and/or faster dissolution of amorphous forms with the stability of crystalline forms. However, the choice of the co-former is critical for the formation of a COAMS. While some models exist to predict the potential formation of COAMS, they often focus on a limited group of compounds. Here, four classes of combinations of an active pharmaceutical ingredient (API) with (1) another API, (2) an amino acid, (3) an organic acid, or (4) another substance were considered. A model using gradient boosting methods was developed to predict the successful formation of COAMS for all four classes. The model was tested on data not seen during training and predicted 15 out of 19 examples correctly. In addition, the model was used to screen for new COAMS in binary systems of two APIs for inhalation therapy, as diseases such as tuberculosis, asthma, and COPD usually require complex multidrug-therapy. Three of these new API-API combinations were selected for experimental testing and co-processed via milling. The experiments confirmed the predictions of the model in all three cases. This data-driven model will facilitate and expedite the screening phase for new binary COAMS.

[1]  Ganesh Bagler,et al.  Machine learning models to predict sweetness of molecules , 2022, Comput. Biol. Medicine.

[2]  Mingchao Yu,et al.  Cocrystal virtual screening based on the XGBoost machine learning model , 2022, Chinese Chemical Letters.

[3]  A. Di Pizio,et al.  Premexotac: Machine Learning Bitterants Predictor for Advancing Pharmaceutical Development. , 2022, International journal of pharmaceutics.

[4]  A. Nokhodchi,et al.  Different trends for preparation of budesonide pellets with enhanced dissolution rate , 2022, Advanced Powder Technology.

[5]  Z. Nagy,et al.  Application of Artificial Neural Networks in the Process Analytical Technology of Pharmaceutical Manufacturing—a Review , 2022, The AAPS Journal.

[6]  P. D. Mavroudis,et al.  Machine-learning-guided early drug discovery of small molecules. , 2022, Drug discovery today.

[7]  Yonghyun Choi,et al.  Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis. , 2021, Journal of bioscience and bioengineering.

[8]  M. McAfee,et al.  Machine Learning for Process Monitoring and Control of Hot-Melt Extrusion: Current State of the Art and Future Directions , 2021, Pharmaceutics.

[9]  Bo Lian,et al.  Applications of Machine Learning in Solid Oral Dosage Form Development. , 2021, Journal of pharmaceutical sciences.

[10]  S. Ibrić,et al.  Application of Machine-Learning Algorithms for Better Understanding of Tableting Properties of Lactose Co-Processed with Lipid Excipients , 2021, Pharmaceutics.

[11]  Swapnil J. Dengale,et al.  Considerations for the Selection of Co-formers in the Preparation of Co-amorphous Formulations. , 2021, International journal of pharmaceutics.

[12]  M. Khanfar,et al.  Preparation and Evaluation of Co-amorphous Formulations of Telmisartan—Amino Acids as a Potential Method for Solubility and Dissolution Enhancement , 2021, AAPS PharmSciTech.

[13]  T. Rades,et al.  Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies , 2021, Pharmaceutics.

[14]  M. Ruponen,et al.  Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs , 2021, Pharmaceutics.

[15]  Xiaojian Zhang,et al.  Drug-drug cocrystals: Opportunities and challenges , 2020, Asian journal of pharmaceutical sciences.

[16]  J. Steed,et al.  Predictive Identification of Co-formers in Co-amorphous Systems. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  Xiaomin Luo,et al.  Machine-Learning-Guided Cocrystal Prediction Based on Large Data Base , 2020 .

[18]  Gaurav Kumar,et al.  MATHEMATICS FOR MACHINE LEARNING , 2020, Journal of Mathematical Sciences & Computational Mathematics.

[19]  T. Rades,et al.  Determination of Stable Co-Amorphous Drug–Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures , 2019, Pharmaceutics.

[20]  T. Rades,et al.  Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy , 2019, AAPS PharmSciTech.

[21]  Ting Cai,et al.  Advances in coamorphous drug delivery systems☆ , 2018, Acta pharmaceutica Sinica. B.

[22]  T. Rades,et al.  Influence of preparation technique on co‐amorphization of carvedilol with acidic amino acids , 2018, International journal of pharmaceutics.

[23]  J. Rantanen,et al.  The use of molecular descriptors in the development of co‐amorphous formulations , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Junliang Fan,et al.  Comparison of Support Vector Machine and Extreme Gradient Boosting for predicting daily global solar radiation using temperature and precipitation in humid subtropical climates: A case study in China , 2018 .

[25]  Tatsuya Takagi,et al.  Mordred: a molecular descriptor calculator , 2018, Journal of Cheminformatics.

[26]  Baochang Cai,et al.  Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile. , 2017, International journal of pharmaceutics.

[27]  M. Hussein,et al.  Nano-Formulation of Ethambutol with Multifunctional Graphene Oxide and Magnetic Nanoparticles Retains Its Anti-Tubercular Activity with Prospects of Improving Chemotherapeutic Efficacy , 2017, Molecules.

[28]  G. Monti,et al.  Preparation of Chloramphenicol/Amino Acid Combinations Exhibiting Enhanced Dissolution Rates and Reduced Drug-Induced Oxidative Stress , 2017, AAPS PharmSciTech.

[29]  O. Korhonen,et al.  Rational excipient selection for co-amorphous formulations , 2017, Expert opinion on drug delivery.

[30]  CRYSTALLINE PHARMACEUTICAL CO-CRYSTALS OF GLYCOPYRRONIUM BROMIDE WITH LACTOSE FIELD OF INVENTION , 2017 .

[31]  T. Rades,et al.  Recent advances in co-amorphous drug formulations. , 2016, Advanced drug delivery reviews.

[32]  Tianqi Chen,et al.  XGBoost: A Scalable Tree Boosting System , 2016, KDD.

[33]  D. Gaspar,et al.  Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies. , 2016, International journal of pharmaceutics.

[34]  H. Ueda,et al.  A Strategy for Co-former Selection to Design Stable Co-amorphous Formations Based on Physicochemical Properties of Non-steroidal Inflammatory Drugs , 2016, Pharmaceutical Research.

[35]  P. Moodley,et al.  Challenges of Tuberculosis Treatment with DOTS: An Immune ImpairmentPerspective , 2015 .

[36]  B. Ripley Classification and Regression Trees , 2015 .

[37]  I. Tucker,et al.  Inhaled dry powder formulations for treating tuberculosis. , 2015, Current drug delivery.

[38]  E. Fattal,et al.  Pulmonary drug delivery systems for tuberculosis treatment. , 2015, International journal of pharmaceutics.

[39]  H. Frijlink,et al.  Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[40]  D. Tashkin,et al.  Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease , 2013, Respiratory Research.

[41]  C. Strachan,et al.  Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  Vesa-Pekka Lehto,et al.  Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory-Huggins interaction parameter and phase diagram. , 2010, Molecular pharmaceutics.

[43]  D. Postma,et al.  Management of Asthma with ICS and LABAs: different treatment strategies , 2009 .

[44]  Vladimir Vapnik,et al.  Support-vector networks , 2004, Machine Learning.

[45]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[46]  J. Friedman Greedy function approximation: A gradient boosting machine. , 2001 .

[47]  Asthma management and prevention. Global Initiative for Asthma. , 2000, Irish medical journal.

[48]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[49]  N. Altman An Introduction to Kernel and Nearest-Neighbor Nonparametric Regression , 1992 .

[50]  W S McCulloch,et al.  A logical calculus of the ideas immanent in nervous activity , 1990, The Philosophy of Artificial Intelligence.

[51]  P. Burman A comparative study of ordinary cross-validation, v-fold cross-validation and the repeated learning-testing methods , 1989 .